Global Retinal Biologics Market: Overview

There has been a remarkable rise in the incidences of diabetes across the globe, which is expected to drive the global retinal biologicsmarket. Mortality, morbidity, and the economic burden related to diabetes related complications have become a public health concern worldwide. Diabetic retinopathy is one of the leading causes of vision loss worldwide. According to the findings of a study on diabetic retinopathy, it has been projected that the number of people suffering from diabetic retinopathy would rise to 629 million through 2045. The same figure stands at 422 mn now.

The global retinal biologics market is likely to exhibit considerable growth clocking a sound rate of growth during the assessment period of 2019-2027. The global retinal biologicsmarket is segmented on the basis of distributional channel, drug class, indication, and region.

Get an Idea about the Offerings of Our Retinal Biologics Market Report from this Brochure

Global Retinal Biologics Market: Notable Developments

There have been some developments in the globalretinal biologicsmarket, one of which is mentioned below:

  • In November 2018, Novartis International AG made an announcement about approval of its one-time gene therapy treatment, Luxturna, by the European Commission (EC). This newly approved therapy will be used in the treatment of patients with vision loss resulting from genetic mutation related to retinal dystrophy gene. To make the treatment successful, the patients need to have substantial usable retinal cells. The U.S.-based Spark Therapeutics commercializes and develops Luxturna in the U.S. 

Some of therenowned companies operating in the global retinal biologicsmarket are as follows

  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Spark Therapeutics, Inc.
  • Amgen Inc.
  • Novartis International AG

Expanding Operations in Future? To Get the Perfect Launch Ask for a Custom Retinal Biologics Market Report

Global Retinal Biologics Market: Key Trends

The following trends and opportunities are likely to be exhibited by the global retinal biologics market over the period of assessment.

Increased Prevalence of Diabetes and Macular Degeneration Escalates Demand for Retinal Biologics

According to American Macular Degeneration Foundation, more than 10 million Americans are affected with macular degeneration. It has emerged as a leading cause for vision loss across the globe. Generally, people above the age of 50 years are prone to suffer from macular degeneration. The global retinal biologicsmarket is expected to derive support from the rising prevalence of macular degeneration worldwide despite availability of improved options of treatment.

Treatments of diabetic macular edema and diabetic retinopathysubstantially include retinal biologics in its therapy. The global retinal biologicsmarket rides high on the back of phenomenal rise of diabetes and complications associated with it.

Diabetic macular edema also emerges as a consequence of diabetic retinopathy leading to the rise in incidences of macula. According to astatistics by Prevent Blindness, an international non-profit organization, nearly 5.3% of the total population in the U.S. is affected with diabetic retinopathy.

VEGF-Aantagonist is mostly prescribed for the treatment of diabetic macular edema and diabetic retinopathy. The global retinal biologics market is also likely to be driven by increasing burden of other diseases related to retina like orbital inflammation and uveitis.

Global Retinal Biologics Market: Geographical Analysis

The global retinal biologics market is split into the principal regions of the Middle East and Africa, Latin America,North America, Europe, and Asia Pacific.

North America is estimated to account for a leading share of the global retinal biologics market. North America is likely to continue to be one of the leading revenue generating regions of the market in times to come. Consistent improvement of the healthcare infrastructure, along with rising cases of retinal disorders, and beneficial reimbursement policies are likely to support growth of the regional market.

Europe is also expected to grow steadily over the period of forecast. Countries like France, Germany, the U.K. and Spain are likely to witness increase in demand for retinal biologics.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Retinal Biologics Market

Pre Book